Acarbose
acarbose
Acarbose is an alpha-glucosidase inhibitor that delays intestinal carbohydrate absorption, blunting postprandial glucose and insulin spikes. Rarely used for diabetes in the US, it has gained attention in the longevity community after extending median lifespan in mice across multiple Interventions Testing Program sites.
Alpha-glucosidase inhibitorPrescription requiredEvidence B
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
Acarbose occupies an unusual position: a second-line diabetes drug with first-line longevity credentials in animal models. The Interventions Testing Program (Aging Cell 2014) found acarbose extended median male mouse lifespan by 22% across three independent sites — a degree of replication few interventions achieve. Mechanistically, acarbose blunts the postprandial glucose and insulin excursions that drive AGE formation, oxidative stress, and beta-cell stress. The STOP-NIDDM trial (Lancet 2002, Chiasson et al) showed acarbose reduced progression from impaired glucose tolerance to type 2 diabetes by 25% and lowered cardiovascular event rates. The MeRIA meta-analysis (Hanefeld 2004) suggested a 35% reduction in myocardial infarction in acarbose-treated diabetics. For high-performance men with elevated postprandial glucose on CGM, normal fasting glucose, and high-carb periods (e.g., endurance athletes refueling), acarbose offers a targeted way to flatten meal-induced spikes without affecting fasting metabolism. The cost is mild gastrointestinal disturbance.
Uses
Label uses (approved)
- Type 2 diabetes mellitus
- Impaired glucose tolerance (in some jurisdictions)
Off-label (educational only)
- Longevity / healthspan — Extended median lifespan in multiple mouse strains in ITP studies, particularly malesmoderate
- Reactive hypoglycemia — Blunts postprandial glucose-insulin spikes that trigger reactive lowsweak
- Postprandial glucose control with non-diabetic glucose variability — Flattens CGM curves in metabolically healthy usersweak
Dosing
Label dose
25 mg three times daily with the first bite of each main meal, titrated up to 50-100 mg three times daily
Off-label / biohacker dose
25-50 mg with carb-heavy meals only
Titration: Start 25 mg with the first bite of the largest meal. Add a second and third dose over 2-4 weeks. Increase to 50 mg per meal only if needed and GI tolerated. Doses above 100 mg three times daily rarely add benefit.
When to take: With the first bite of each carbohydrate-containing meal
Side effects & warnings
Common
- Flatulence
- Diarrhea
- Abdominal cramping
- Bloating
- Soft stools
Uncommon but serious
- Elevated liver enzymes at doses >300 mg/day (uncommon)
- Hypoglycemia when combined with insulin (must be treated with glucose, not sucrose)
- Ileus (rare)
- Rare hypersensitivity reactions
Serious warnings
Acarbose-induced hypoglycemia cannot be reversed with sucrose (table sugar) or complex carbs because the drug blocks their breakdown — pure glucose tablets or gel are required. Avoid in inflammatory bowel disease, partial intestinal obstruction, or any condition predisposing to ileus. Liver enzymes can rise reversibly at high doses; check ALT/AST at 3-6 months. Severe flatulence is socially limiting and the leading reason for discontinuation.
Biomarkers affected
fasting glucose
decreaseSmaller effect than metformin on fasting glucose; primary action is postprandial
Evidence: moderate
fasting insulin
decreaseReduced postprandial glucose load lowers chronic insulin demand
Evidence: moderate
hba1c
decreaseReduces HbA1c by 0.5-0.8% via flattening of postprandial peaks (STOP-NIDDM)
Evidence: strong
homa ir
decreaseImprovements via reduced postprandial insulin demand
Evidence: moderate
hscrp
decreaseSmall reductions reported in MeRIA and post-hoc analyses
Evidence: weak
triglycerides
decreasePostprandial triglyceride excursions blunted; modest fasting reductions
Evidence: moderate
Monitoring
ALT/AST at baseline and every 3-6 months for first year if dose >150 mg/day
The honest risk picture
## What can go wrong
**Flatulence and bloating** are the dominant side effects and the reason most people quit. Undigested carbohydrate ferments in the colon, generating hydrogen, methane, and CO2. Severity correlates with carbohydrate load — a low-carb meal produces minimal symptoms. Most users adapt over 2-4 weeks.
**Diarrhea** affects 30% of users initially. It usually resolves with continued use or by reducing the dose.
**Hypoglycemia management is tricky.** Because acarbose blocks sucrose breakdown, table sugar will not rescue a hypoglycemic episode. Anyone combining acarbose with insulin or sulfonylureas must carry glucose tablets or gel, not candy.
**Liver enzyme elevations** occur at doses above 300 mg/day, especially in patients under 60 kg. They reverse on dose reduction. Check ALT/AST at 3 and 6 months if using higher doses long-term.
**Inflammatory bowel disease, partial obstruction, and chronic intestinal disease** are contraindications — slowed transit and fermentation can precipitate ileus.
**Drug interactions** are minimal but acarbose can reduce digoxin absorption.
Practical context
Cost (US, retail)
$15/mo
Legality
Prescription in US (less commonly prescribed); widely available in Europe and Asia
Interactions
false
FAQ
Why is acarbose interesting for longevity?+
The NIA Interventions Testing Program found acarbose extended median lifespan in genetically heterogeneous mice across multiple sites — one of only a handful of drugs to do so. The effect was stronger in males. Mechanism likely involves attenuated postprandial glucose-insulin excursions and gut microbiome shifts.
How does acarbose differ from metformin?+
Metformin lowers fasting glucose by suppressing liver glucose output. Acarbose lowers postprandial glucose by slowing carbohydrate absorption. They are complementary and can be combined.
Will I have severe gas?+
Yes, especially initially. Undigested carbohydrate ferments in the colon. Most users adapt within 2-4 weeks, and a low-carb meal causes less gas than a high-carb one.
Does acarbose cause weight loss?+
Modestly — usually 1-2 kg over 12 months, largely from reduced caloric absorption and appetite changes.
Can I take acarbose only with my biggest meal?+
Yes, this is a common longevity-protocol approach: take 50 mg with the carbohydrate-heaviest meal of the day to flatten the largest glucose spike.
References (4)+
- Acarbose for prevention of type 2 diabetes mellitus: STOP-NIDDM trial. Lancet 2002 (Chiasson et al). https://pubmed.ncbi.nlm.nih.gov/12086760/
- Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan (ITP). Aging Cell 2014. https://pubmed.ncbi.nlm.nih.gov/24895269/
- Effects of acarbose on cardiovascular events in patients with IGT: MeRIA meta-analysis. Eur Heart J 2004 (Hanefeld). https://pubmed.ncbi.nlm.nih.gov/14683737/
- Acarbose treatment and the risk of cardiovascular disease in type 2 diabetes. Diabetes Care 2008. https://pubmed.ncbi.nlm.nih.gov/18000183/
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.